TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Comparison

Zepbound vs Compounded Tirzepatide

Same fields, same evidence rules, both sides. No preselected winner.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

This comparison sets out where the two options genuinely differ — mechanism, regulatory status, evidence base, cost path and practical trade-offs — and where the difference is smaller than it is usually presented. It does not recommend one for you.

Answer last reviewed:
Approved product against compounded preparation
Approved product against compounded preparation
AttributeFDA-approved tirzepatide (Zepbound, Mounjaro)Compounded tirzepatide
Regulatory statusApproved finished drug productNot an FDA-approved product
Generic equivalentNo generic tirzepatide existsNot a generic and not therapeutically equivalent
Manufacturing standardManufactured under CGMPDepends on the compounder's registration class
Clinical trial evidenceStudied in the registration trialsTrials studied the approved product, not this preparation
LabellingFDA-approved labellingSupplied by the compounder
PresentationManufacturer's pens or vialsVaries; multi-dose vials add a measuring step
Price read on the seller’s own page——

A dash means no figure held. How we grade evidence.

No provider may describe a compounded preparation as FDA-approved or as generic Zepbound. Both statements are false, and both are common.
503A pharmacy against 503B outsourcing facilityStatutory distinction · pending legal review
503A pharmacy against 503B outsourcing facility
Requirement503A compounding pharmacy503B outsourcing facility
Compounds pursuant toA prescription for an identified individual patientMay compound without patient-specific prescriptions
FDA registrationNot registered as an outsourcing facilityRegisters with FDA
CGMP requirementsNot required to meet CGMPMust comply with CGMP — though registration alone is not evidence of compliance
Primary oversightState board of pharmacyFDA, on a risk-based inspection schedule
Adverse-event reportingNot required under 503ARequired to report adverse events to FDA
Product approval statusNot an FDA-approved productNot an FDA-approved product
What registration establishesNot applicableFDA received the required information, nothing more Verified
Neither route produces an FDA-approved medicine. Registration and inspection are not approval, and no accreditation changes that.
Official verification routescaptured 2026-07-26

Every one of these is the register held by the body that issues the credential. A claim checked against the page that made it has not been checked.

Why 'cheapest' needs a definition attached
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.
Where the cost difference actually sits
MedicationOption A — not capturedOption B — not capturedRequired feesOption A — not capturedOption B — not capturedTwelve-month totalOption A — not capturedOption B — not capturedOption AOption B
Show this figure as a table
Data table
ItemOption AOption B
Medicationnot capturednot captured
Required feesnot capturednot captured
Twelve-month totalnot capturednot captured
Filled from captured records. An empty bar is a gap in our research, not a zero.

The short version

Zepbound is Lilly's FDA-approved tirzepatide for chronic weight management, and for moderate-to-severe obstructive sleep apnea in adults with obesity. Compounded tirzepatide is a pharmacy-made preparation. It is made with the drug in Zepbound, but it is not the same product: it has no FDA approval for any use, and no trial has tested it.

Zepbound fits best when something lowers its price. That could be insurance, the Medicare GLP-1 Bridge ($50 a fill for eligible enrollees, KwikPen only) or Lilly's self-pay pricing at the starting doses. Compounded tirzepatide is mostly chosen by people paying cash at higher doses. There, the October 2026 index median of $149 a month sits well below Lilly's $449 refill price. The cost of that saving is less regulatory assurance.

Where they actually differ

  • What it is approved for. Zepbound's label covers weight management and moderate-to-severe obstructive sleep apnea with obesity. Compounded tirzepatide is not approved for anything.
  • The device. Zepbound comes as a Lilly-made prefilled pen or single-dose vials. Compounded tirzepatide usually comes in a multi-dose vial and a syringe. Your dose then depends on reading the concentration and the syringe correctly, and FDA says to discard the vial within 28 days of first use.
  • How you pay. Zepbound can go through insurance, the Medicare Bridge (KwikPen only, not vials) or Lilly's self-pay pricing. Compounded tirzepatide is almost always paid in cash.
  • Supply chain. Zepbound comes from Lilly through pharmacies or LillyDirect. A compounded vial comes from whichever pharmacy your program uses, so you need to know its name. NexLife, for example, names three state-licensed 503A pharmacies.
  • Evidence. SURMOUNT-1's −20.9% mean weight change at 15 mg over 72 weeks (treatment-regimen estimand) describes the approved product. It is not a result for a compounded vial.

Where they are more similar than claimed

  • The dose ladder. Zepbound's label starts at 2.5 mg weekly for four weeks, then raises the dose in 2.5 mg steps at least four weeks apart. A compounded prescription can use the same steps, so ask your prescriber what schedule you are on.
  • Getting a prescription. Both need one from a licensed clinician, and both are widely prescribed by telehealth. A Zepbound prescription is not automatically better supervised than a compounded one. The provider decides that.
  • The starting price. At 2.5 mg, Lilly's self-pay price is $299 against a compounded median of $149. The gap is real but smaller than at maintenance doses, where it is $449 against $144.
  • Side effects to expect. Stomach and bowel side effects dominate in the Zepbound trials. There is no evidence that compounded versions avoid them.
  • What happens if you stop. In SURMOUNT-4, people switched to placebo regained weight. That is a property of stopping the drug, not of the brand.

Cost, all-in

Over a year at a maintenance dose, using prices read on October 15, 2026 and November 6, 2026:

RoutePer month or fillYear
Zepbound KwikPen, self-pay, every refill within 45 days$449 (7.5 to 15 mg)$4,939 for the maximum 11 fills
Zepbound KwikPen, refill window missed$499 (7.5 mg), $699 (10 to 15 mg)Depends on how often
Zepbound KwikPen, Medicare GLP-1 Bridge$50 copayEligible enrollees only
Compounded tirzepatide, index median$144$1,728
NexLife, 12-month plan$115, same at every dose, no membership$1,380

NexLife is not the lowest figure in the index: three programs list lower monthly prices. Lilly's self-pay savings end on December 31, 2026. Re-check both on the price index and the Zepbound savings page.

Who each option suits

These are situations, not recommendations. The prescribing decision is your clinician's.

  • You have moderate-to-severe obstructive sleep apnea and obesity. Zepbound is approved for this. Compounded tirzepatide is not. On Medicare, you are not eligible for the GLP-1 Bridge, but your Part D plan might cover a GLP-1.
  • You are on Medicare, with obesity and without type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. The Bridge's $50 copay for the Zepbound KwikPen may apply. Check eligibility with CMS.
  • Your commercial plan covers Zepbound. Your copay may beat any cash route.
  • You pay cash and stay at 2.5 mg or 5 mg. Compare $299 or $399 against your compounded quote over twelve months.
  • You pay cash at maintenance doses and are comfortable with vials. Compounded is where the saving is. Check the pharmacy first.

What the evidence does not settle

  • A head-to-head comparison. No trial has compared Zepbound with any compounded tirzepatide.
  • Sleep apnea results. SURMOUNT-OSA tested the approved product at 10 mg or 15 mg. Whether a compounded vial produces the same change in breathing events is unknown.
  • Dose accuracy at home. How often people measure the wrong amount from a multi-dose vial is not known. FDA has adverse event reports from dosing errors with compounded GLP-1s, but no rate.
  • Heart outcomes. Even for Zepbound, the effect on heart attacks, strokes and deaths in people with obesity is the subject of SURMOUNT-MMO (NCT05556512). The 2024 SURMOUNT-OSA paper described that trial as ongoing.
  • Prices after 2026. Lilly's self-pay savings end on December 31, 2026. We do not know what, if anything, will replace them.

Where it holds up

  • nothing verified yet

Where it does not

  • nothing verified yet

Questions readers actually ask

Is compounded tirzepatide the same as Zepbound or Mounjaro?

No: compounded tirzepatide is made with the drug in Zepbound and Mounjaro, but it is not the same product, because it is not FDA-approved, it is not a generic, and it is not the product Eli Lilly tested in the SURMOUNT and SURPASS trials. Zepbound and Mounjaro are made under FDA-approved manufacturing and labeling. A compounded preparation depends on the pharmacy that makes it, often comes as a multi-dose vial you measure yourself, and may include added ingredients. Trial results such as the 20.9% average weight loss at 15 mg in SURMOUNT-1 describe Lilly's product, not a compounded version.

Which one is better?

Neither, in the abstract. The comparison table shows where each is stronger on a defined field; the right answer depends on your dose, your billing term and what your clinician advises.

Is one of these sponsoring this page?

No. No provider can buy a score, a placement or a review on this site.

NexLife, first on our v4.1 methodology, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan, with one price at every dose and no membership fee (read on nexlife.us, November 6, 2026). Check its current plans (opens nexlife.us in a new tab).

Cite this pageCC BY 4.0

Tirzepatide Ranked. “Zepbound vs Compounded Tirzepatide.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/zepbound-vs-compounded-tirzepatide/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error
Comparing 0 of 4